ArticleScientific reports2019
Association of Anticholinergic Use with Incidence of Alzheimer's Disease: Population-based Cohort Study.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome.The Cochrane database of systematic reviews · 2021Pooled it
- Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis.Neurourology and urodynamics · 2021Pooled it
- Exposome influences: a multi-omics perspective on the combined toxic effects of pharmaceuticals and personal care products in Alzheimer's disease.Frontiers in toxicology · 2026Review
- Anticholinergic burden and incident dementia: a Swedish nationwide case-control study.Alzheimer's research & therapy · 2025Article
- Medication Exposure and Risk of Dementia and Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Anticholinergic exposure and its association with dementia/Alzheimer's disease and mortality in older adults.BMC geriatrics · 2023Article
- Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale.BMC geriatrics · 2020Article
- Anticholinergic Drugs Interact With Neuroprotective Chaperone L-PGDS and Modulate Cytotoxicity of Aβ Amyloids.Frontiers in pharmacology · 2020Article
- Prevalence of potentially inappropriate prescriptions in primary care and correlates with mild cognitive impairment.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs with strong anticholinergic properties are used under a variety of conditions; however, they can cause various adverse effects including a negative impact on cognitive functions, with older adults being more susceptible to these effects. We explored whether the use of anticholinergic agents (ACs) affects the risk of Alzheimer's disease (AD) in terms of incidence by using National Health Insurance Service elderly cohort database (2002-2013). As a result, AD risk was higher in subjects with an increased amount of prescriptions for strong ACs over a long period of time (9-12 years) than that in the least-exposed reference group (0-9 dose/year) [hazard ratio (HR) (95% confidence interval (95% CI)) 0.99 (0.95-1.03), 1.19 (1.12-1.26), 1.39 (1.30-1.50); in the 10-49 doses/year, 50-119 doses/year, and ≥120 doses/year groups]. Hazard ratios were particularly high in the young-old subgroup (60-64 years old in 2002) [HR (95% CI) 1.11 (1.04-1.22), 1.43 (1.25-1.65), 1.83 (1.56-2.14); in the 10-49 doses/year, 50-119 doses/year, and ≥120 doses/year groups]. Use of strong ACs dose-dependently increased the risk of AD in terms of incidence when exposure was followed up for 9 years or more, and the association was greater in the young-old subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.